Literature DB >> 10376166

Platelet nitric oxide metabolites in migraine.

T Shimomura1, F Murakami, K Kotani, S Ikawa, S Kono.   

Abstract

Nitric oxide (NO) is a candidate as a causative molecule in migraine. We determined nitrite, total nitrate/nitrite, and cyclic guanosine 3',5'-monophosphate (cGMP) concentrations in platelets from 30 migraine without aura (MwoA) patients and 17 migraine with aura (MwA) patients. All migraine patients were studied during their migraine attacks. The control group consisted of 28 healthy volunteers. Concentrations of platelet nitrite and total nitrate/nitrite were determined using simple and sensitive nitrate/nitrite fluorometric assay techniques. High concentrations of platelet nitrite and total nitrate/nitrite were found in patients with MwoA and MwA when compared with healthy controls. High concentrations of platelet cGMP were also found in patients with MwoA and MwA. The levels of platelet total nitrate/nitrite significantly decreased in headache-free periods after treatment with oral propranolol. These findings suggest that NO is produced in platelets during migraine attacks. It may also be related to the migrainous pain and the changes in cerebral blood flow experienced during migraine attacks. These data may provide new strategies for the treatment of migraine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376166     DOI: 10.1046/j.1468-2982.1999.019004218.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  10 in total

Review 1.  The role of nitric oxide in nociception.

Authors:  Z D Luo; D Cizkova
Journal:  Curr Rev Pain       Date:  2000

2.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

Review 3.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 4.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

5.  Decreased antioxidant status in migraine patients with brain white matter hyperintensities.

Authors:  Bilal Aytaç; Özlem Coşkun; Bülent Alioğlu; Zahide Esra Durak; Süleyman Büber; Esra Tapçi; Ruhşen Ocal; Levent Ertuğrul Inan; İlker Durak; Tahir Kurtuluş Yoldaş
Journal:  Neurol Sci       Date:  2014-07-10       Impact factor: 3.307

6.  A novel oxidative stress marker in migraine patients: dynamic thiol-disulphide homeostasis.

Authors:  Sadiye Gumusyayla; Gonul Vural; Hesna Bektas; Salim Neselioglu; Orhan Deniz; Ozcan Erel
Journal:  Neurol Sci       Date:  2016-05-03       Impact factor: 3.307

7.  Increased asymmetric dimethylarginine and nitric oxide levels in patients with migraine.

Authors:  Ertugrul Uzar; Osman Evliyaoglu; Gülten Toprak; Abdullah Acar; Yavuz Yucel; Tugba Calisir; Mehmet Ugur Cevik; Nebahat Tasdemir
Journal:  J Headache Pain       Date:  2011-02-27       Impact factor: 7.277

8.  Analysis of NOS Gene Polymorphisms in Relation to Cluster Headache and Predisposing Factors in Sweden.

Authors:  Caroline Ran; Julia M Michalska; Carmen Fourier; Christina Sjöstrand; Elisabet Waldenlind; Anna Steinberg; Andrea C Belin
Journal:  Brain Sci       Date:  2020-12-31

Review 9.  The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders.

Authors:  Manish Kumar Tripathi; Maryam Kartawy; Haitham Amal
Journal:  Redox Biol       Date:  2020-05-15       Impact factor: 11.799

10.  A 16S rRNA gene sequencing based study of oral microbiota in migraine patients in China.

Authors:  Weiqing Jiang; Tingting Wang; Chen Liu; Mingzhu Deng; Xiao Ren; Fei Wang; Yaqing Zhang; Xueying Yu; Lingling Yao; Yonggang Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.